HopeStage
Back to all studies
Active Not RecruitingNCT06786325

Psilocybin and brain and clinical measures in opioid use disorder

About this titleRead the official source — NCT06786325
Medication studyAges 18–60United StatesAddiction
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 60 years.

Listed locations
PhiladelphiaSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: October 7, 2025
Recruitment status
Active Not Recruiting
Enrollment listed in the registry
36
Sponsor
Anna Rose Childress, Ph.D.
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 60 Years
Official registry ID
NCT06786325
Official title
Show the full official title

A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?

Recruitment & locations

Not recruiting

Philadelphia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Anna Rose Childress, Ph.D.

Does this study involve medication?

Yes. The study involves medication, including Psilocybin.

Who can participate?

Listed age limits: 18 years to 60 years.

Is this study still recruiting?

The registry lists this study as active, but no longer recruiting.

Want to explore more studies?

Explore studies